MTNB Projected Dividend Yield
Matinas BioPharma Holdings Inc ( AMEX : MTNB )Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. Co. is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. 20 YEAR PERFORMANCE RESULTS |
MTNB Dividend History Detail MTNB Dividend News MTNB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |